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Abstract: In humans the switch from fetal to adult  hemoglobin (HbF
the perinatal  and  postnatal  period,  determining  the progressive replacement  of  HbF with 
HbA synthesis ( i.e., the relative HbF content in red blood cells decreases from 80
<1%). In spite of more than twenty years of intensive investigations on this classic model, the 
molecular mechanisms regulating the Hb switching, as well as HbF synthesis in adults, has 
been only in part elucidated. In adult life, the residual HbF, restr
may be reactivated up to 10-20% of total Hb synthesis in various conditions associated with 
“stress erythropoiesis”: this reactivation represented until now an interesting model of partial 
Hb  switch  reverse  with  important  thera
hemoglobinopathies, and particularly in 
the identification of several chemical compounds able to reactivate HbF synthesis in adult 
erythroid  cells.  Although  the  imp
agents, histone deacetylase inhibitors and hydroxyurea, was clear on the natural history of 
sickle  cell  anemia,  the  benefit  on  the  clinical  course  of 
particularly, the toxicity and the modest increase in γ
for improved agents able to induce higher levels of HbF. In the present review we describe the 
biologic  properties  of  Stem  Cell  Factor  (SCF),  a  cytokine  sustaining  the  survival  and 
proliferation of erythroid cells, that at pharmacological doses acts as a potent stimulator of 
HbF synthesis in adult erythroid cells. 
Introduction: Worldwide, thalassemia is one of the 
most common  genetic  diseases. It affects  peoples 
who originate from the Mediterranean areas through 
the  Middle  East  to  the  Indian  subcontinent  and 
Southeast  Asia
1.  The  thalassemia  syndromes  are 
broadly classified into two groups: 
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In humans the switch from fetal to adult  hemoglobin (HbF→ HbA) takes place in 
the perinatal  and  postnatal  period,  determining  the progressive replacement  of  HbF with 
HbA synthesis ( i.e., the relative HbF content in red blood cells decreases from 80
<1%). In spite of more than twenty years of intensive investigations on this classic model, the 
molecular mechanisms regulating the Hb switching, as well as HbF synthesis in adults, has 
been only in part elucidated. In adult life, the residual HbF, restricted to F cell compartment, 
20% of total Hb synthesis in various conditions associated with 
“stress erythropoiesis”: this reactivation represented until now an interesting model of partial 
Hb  switch  reverse  with  important  therapeutic  implications  in  patients  with 
hemoglobinopathies, and particularly in -thalassemia. In vitro and in vivo
the identification of several chemical compounds able to reactivate HbF synthesis in adult 
erythroid  cells.  Although  the  impact  of  these  HbF  inducers,  including  hypomethylating 
agents, histone deacetylase inhibitors and hydroxyurea, was clear on the natural history of 
sickle  cell  anemia,  the  benefit  on  the  clinical  course  of  -thalassemia  was  only  limited: 
icity and the modest increase in γ-globin reactivation indicated the need 
for improved agents able to induce higher levels of HbF. In the present review we describe the 
biologic  properties  of  Stem  Cell  Factor  (SCF),  a  cytokine  sustaining  the  survival  and 
roliferation of erythroid cells, that at pharmacological doses acts as a potent stimulator of 
HbF synthesis in adult erythroid cells. 
Worldwide, thalassemia is one of the 
most common  genetic  diseases. It affects  peoples 
who originate from the Mediterranean areas through 
ubcontinent  and 
.  The  thalassemia  syndromes  are 
wo groups: -thalassemia, 
in which the -globin chain synthesis is defective; 
and -thalassemia, which results from defective 
globin  chain  synthesis.  
commonly caused by gene deletions that affect one 
or both of the duplicated 
form of -thalassemia, common in Southeast Asia, 
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→ HbA) takes place in 
the perinatal  and  postnatal  period,  determining  the progressive replacement  of  HbF with 
HbA synthesis ( i.e., the relative HbF content in red blood cells decreases from 80-90% to 
<1%). In spite of more than twenty years of intensive investigations on this classic model, the 
molecular mechanisms regulating the Hb switching, as well as HbF synthesis in adults, has 
icted to F cell compartment, 
20% of total Hb synthesis in various conditions associated with 
“stress erythropoiesis”: this reactivation represented until now an interesting model of partial 
peutic  implications  in  patients  with 
in vivo models have led to 
the identification of several chemical compounds able to reactivate HbF synthesis in adult 
act  of  these  HbF  inducers,  including  hypomethylating 
agents, histone deacetylase inhibitors and hydroxyurea, was clear on the natural history of 
thalassemia  was  only  limited: 
globin reactivation indicated the need 
for improved agents able to induce higher levels of HbF. In the present review we describe the 
biologic  properties  of  Stem  Cell  Factor  (SCF),  a  cytokine  sustaining  the  survival  and 
roliferation of erythroid cells, that at pharmacological doses acts as a potent stimulator of 
globin chain synthesis is defective; 
thalassemia, which results from defective -
-thalassemia  is  most 
commonly caused by gene deletions that affect one 
-globin loci. The severe 
thalassemia, common in Southeast Asia, Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
is  caused  by  deletion  of  the  duplicated  -globin 
genes, and the majority of homozygous fetuses die 
at the third trimester of pregnancy or at birth. In -
thalassemia the common molecular defects are the 
results of some mutations (point mutations or small 
deletions) that affect the transcription, splicing, or 
translation  of  the  mRNA.  Newborns  with 
homozygous -thalassemia are healthy, but as the 
hemoglobin  switches  from  fetal  to  adult 
hemoglobin synthesis just after birth, the lack of -
globin chain synthesis results in the development of 
progressive anemia. In these patients the degree of 
anemia  may  vary  depending  on  the  degree  of  -
globin chain deficiency, but the  majority of them 
have severe  anemia  requiring  life-long  blood 
transfusions  and,  consequently,  iron  chelation. 
Hence,  -thalassemia  represents  a  severe  health 
problem and many therapeutic strategies have been 
attempted.
Cure of -thalassemia can be achieved by bone 
marrow  or  cord  blood  transplantations  if 
histocompatible  donors  are  available
2.  However, 
since  these  patients’  families  are  usually  small, 
perfectly histocompatible donors are not commonly 
found.  In  addition,  graft  versus  host  disease  of 
variable  severity  usually  follows  and  complicates 
the  clinical  course  of  these  transplantations.  The 
other  approach  of  curative  treatment  of  -
thalassemia  consists  in  the  gene  therapy,  but  this 
approach is only at the beginning and till now very 
few  patients  have been  treated
3;  furthermore, this 
treatment is not on the point of  receiving a marked 
clinical development in the next years.
An  alternative  treatment  of  -thalassemia 
consists in the pharmacological stimulation of fetal 
hemoglobin  (HbF)  synthesis.  In  humans, 
hemoglobin switch from HbF to adult hemoglobin 
(HbA) occurs in the period around birth as a result 
of  - to  -globin  gene  switching.  This  switching 
requires  developmental  stage-specific  changes  in 
the expression/function of transcription factors and 
chromatin  remodeling  activities  that  induce 
repression  of  -globin  gene  expression  and/or 
induction  of  -globin  gene  expression
4,5.  HbF  is 
synthesized  at  very  low  levels  in  adults, 
representing  less  than  1%  of  total  hemoglobin
6. 
Moreover,  the  level  of  HbF  is  inherited  as  a 
quantitative  trait  and  is  of  enormous  clinical 
relevance, given its role in ameliorating the severity 
of  the  main  hemoglobin  diseases,  including  -
thalassemia  and  drepanocytosis.  Recent  genome-
wide association studies have identified three major 
loci  containing  a  set  of  five  common  single-
nucleotide polymorphisms (SNPs) that account for 
20% of the variation in HbF levels
7-9. Importantly, 
several of these variants predict the clinical severity 
of  sickle cell  disease
7 and of -thalassemia
8.  The 
SNP  with  the  largest  effects  on  HbF  synthesis is 
located in the second intron of a gene present on 
chromosome 2, encoding BCL11A. A recent study 
has  provided  clear  evidence  that  BCL11A  is  an 
important  regulator  of  HbF  expression.  BCL11A 
acts  as  a  repressor  of  HbF  synthesis  and  its 
expression,  is low  in  fetal  erythroid  cells,  is 
abundant in adult erythroid cells; downregulation of 
BCL11A  in  adults  erythroid  cells  leads  to  a 
remarkable  HbF  expression
10.  Another  SNP  that 
plays  an  important  role  in  the  control  of  HbF 
synthesis  is  located  at  the  level  of  HBS1L-MYB 
intergenic region on chromosome 6q23: this locus 
contains  regulatory  sequences  that  play  an 
important role in the control of HbF synthesis and 
hematopoiesis by controlling MYB expression
11.
The -globin gene transcription is controlled by 
complex molecular mechanisms involving both cis-
acting elements, represented by specific nucleotide 
sequences,  such  as  Locus  Control  Region  (LCR) 
and  trans-acting  elements,  such  as  transcription 
factors  and  chromatin  remodeling  activities
4.  The 
human -globin LCR was functionally defined as a 
DNA  regulatory  region  conferring  high  levels  of 
erythroid-speciifc expression to a cis-linked gene in 
a copy-dependent manner, which is independent of 
the integration site. GATA-1, EKLF and NF-E2 are 
the best known tissue-specific transcription factors 
involved  in  the  transcriptional  control  of  -like 
globin  genes.  GATA-1  and  EKLF  transcription 
factors are essential  for an active chromatine hub 
(ACH) formation.
Important  informations  on  cis-elements 
regulating -globin gene expression derive from the 
analysis of the mutations occurring at the -globin 
locus  in  patients  with  increased  HbF  (Hereditary 
Persistance of Fetal Hemoglobin) (reviewed in 12). 
Two  types  of  HPFH  have  been  identified:  non-
deletion  and  deletion-type  HPFH.  Non-deletion 
HPFHs are due to mutations occurring in either the 
G or 
A-globin  gene  promoters,  thus  resulting  in 
continued HbF synthesis in adult life. These non-
deletion  HPFH  mutations  are  clustered  in  three 
regions of the -globin promoters, at the level of the 
positions  -200,  -175  and  -115  relative  to the 
transcription  site
13.  The  increased  HbF  synthesis 
observed  in  adults  carrying  non-deletion  HPFH 
mutations are due to either a decreased binding of 
transcription  repressors  inhibiting  -globin  gene 
expression or to the generation of binding sites that Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
potentiate the binding of a transcriptional complex 
increasing -globin gene transcription. On the other 
hand, the analysis of the DNA deletions as well as 
of  the  phenotype  of  deletion-type  HPFH  has 
provided important information’s on the existence 
of  DNA  sequences  of  the  -globin  gene  cluster 
affecting -globin gene expression. In the African 
type of deletion HPFH, large deletions have been 
observed involving intergenic - sequences and the 
entire  and  genes. The phenotype of these HPFH 
forms is seemingly related to the juxtaposition of 
enhancer elements, normally located downstream of 
the globin locus, and the HPFH breakpoint exerting 
a  positive  stimulatory  effect  on  -globin 
transcription
14.  The  analysis  of  the  gene  deletion 
occurring in  thalassemia and, particularly in ° 
Corfu  deletion  strongly  supports  the  notion  that 
intergenic - sequences play a key role in the adult 
-globin reactivation. 
In addition to genetic elements present in the -
globin locus, also genetic elements present outside 
this locus control the level of HbF synthesis during 
the adult life
7-10. These genetic elements contribute 
to  inter-individual  variation  in  HbF  expression 
representing  a  heritable  disease  modifier
15.  Three 
major  loci  – Xmn1-HBG2  single  nucleotide 
polymorphism, HBS1L-MYB intergenic region on 
chromosome  6q,  and  BC11A- contribute  to  HbF 
variation  in  healthy  European  Caucasians  and  -
thalassemia  and  sickle  cell  traits
15.  These  HbF 
quantitative trait loci and others not yet discovered, 
besides accounting  for the common HbF variation 
in healthy adults, play also an important role in the 
variation  of  HbF  production  in  response  to 
erythropoietic stress, and possibly, in the capacity to 
respond  to  pharmacological  stimulators  of  HbF 
synthesis
16. It is of interest to note that two of these 
quantitative  trait  loci  include  oncogenes, 
emphasizing  the  importance  of  cell  proliferation 
and differentiation as an important contribution to 
the HbF phenotype
17.
Finally, an important role in the control of globin 
gene  expression  is  played  also  by  chromatin 
epigenetic changes. The main chromatin epigenetic 
changes  occur  at  the  level  of  core  histones  and 
consist  in  covalent  modifications  such  as 
acetylation,  methylation  and  phosphorylation. 
Among these modifications a relevant role is played 
by  histone  acetylation  in  the  control  of  -globin 
gene  expression:  active  -globin  genes  are  highly 
acetylated,  while  reactive  .globin  genes  are 
scarcely  or  only  midly  acetylated
18.  Histone 
methylation plays also an important role in -globin 
gene expression: a low histone methylation at the 
level  of  the  -globin  gene  promoter  is  associated 
with elevated HbF synthesis, while a high level of 
histone methylation is linked to repression of HbF 
synthesis
19.
Chemical inducers of HbF synthesis: The analysis 
of  the  molecular  mechanisms  underlying 
hemoglobin  switching  and,  particularly  -globin 
gene  expression,  have  greatly  contributed  to  the 
identification,  study  and  possible  clinical 
development  of  chemical  compounds  able  to 
reactivate HbF synthesis in adult erythroid cells. A 
fundamental input to the search of  efficient HbF 
chemical inducers came from the observation, made 
several  decades  ago,  that  HbF  may  have  a 
protective  effect  in  sickle  cell  anemia  and  -
thalassemia
20.
During the last 30 years a considerable number 
of  pharmacological  agents  able  to  reactivate  HbF 
synthesis  have  been  identified.  Some  of  these 
agents  have  been  introduced  for  the  treatment  of 
sickle cell anemia and -thalassemia. According to 
their  mechanism  of  action these  compounds have 
been classified in various groups: hypomethylating 
agents,  histone  deacetylase  inhibitors  and 
hydroxyurea.  For  the  analysis  of  the  chemical 
structure and the biologic properties of these HbF 
inducers  the  readers  may  refer  to  some  recent 
reviews
21,20,22. 
The past experimental and clinical observations 
in  the  treatment  of  hemoglobinopathies  supported 
the  basic  conception  that  these  chemical  agents 
represent a rational approach for sickle cell anemia 
and  -thalassemia  therapy.  However,  it  must  be 
pointed  out  that,  while  the  effect  of  these 
pharmacological  treatments  on  sickle  cell  anemia 
was clear, their benefit on the clinical course of -
thalassemia  was  only  limited.  The  discrepancy 
between  these  two  hemoglobinopathies  in  the 
response to HbF inducers may be mainly related to 
the higher level of HbF required in -thalassemia to 
achieve  clinical  results  comparable  to  those 
observed in sickle cell anemia. Furthermore, it was 
recently suggested that the limited clinical response 
to -globin inducers, observed in the majority of -
thalassemic  patients,  may  be  also  a  reflection  of 
unfavorable  effects  of  these  agents  on  the  other 
globin genes (i.e., increased -globin synthesis)
23. 
This observation suggests that other agents able to 
induce  higher  HbF  levels  are  required  for  an 
efficient -thalassemia treatment.
Recently,  the  gene  therapy  approach  was  also 
used  to  increase  the  level  of  HbF  synthesis  inMedit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Figure 1. Schematic representations of the SCF/c-kit cell signaling. The main pathways activated by the activation of the c-kit 
receptor are outlined. The pathways seemingly involce in HbF reactivation are outlined.
-thalassemic  erythroid  cells.  Particularly,  it  was 
shown that amelioration of a murine model of -
thalassemia can be achieved through in vivo drug 
selection  of  hematopoietic  stem  cells  transduced 
with  a  dual  -globin/methylguanine 
methyltransferase lentiviral vector
24.
In the present review we describe the biologic 
properties of Stem Cell Factor (SCF also known as 
Kit  Ligand),  a  cytokine  that,  besides  sustaining 
survival, stimulating hematopoietic progenitor cell 
proliferation  and  enhancing  proliferative  response 
to erythropoietin, at pharmacological doses acts as a 
potent  stimulator  of  HbF  synthesis  in  adult 
erythroid cells.
Role  of  SCF  in  the  control  of  erythropoiesis:
Erythropoiesis  is  subject  to  a  complex  regulation 
via a network of cytokine receptor systems that act 
at  the  level  of  various  stages  during  erythroid 
differentiation and maturation. Erythopoietin (Epo) 
is  an  essential  key  regulator  of  erythropoiesis, 
mainly acting as a cytokine promoting the survival 
and  proliferation  of  late  erythroid  progenitors 
(CFU-E). The growth of early erythroid progenitors 
(BFU-E)  is  promoted  by  various  interleukins, 
including IL-3, IL-11, IL-4 and IL-12. In addition, 
erythropoiesis is regulated by a series of receptor 
tyrosine kinases (RTKs). Among them, a relevant 
role  is  played  by  RON  (c-met-related  tyrosine 
kinase) and its ligand that exert a stimulatory effect 
on  BFU-E  proliferation
25,  Insulin-Like-Growth 
Factor and its receptors stimulating late stages of 
erythropoiesis
26 and  EPHB4  that  exerts  a 
stimulatory  effect  on  erythropoiesis  at  various 
differentiation stages
27.
Particularly, an  important role in the control of 
erythropoiesis  is  played  by  SCF  and  its  receptor 
(SCF-R or c-kit). The initial observations leading to 
discover a role of this cytokine  in erythropoiesis 
derived  from  the  analysis  of  mice  exhibiting 
mutations in the SCF gene, Steel (Sl), or its receptor 
c-kit:  these  mice  develop  severe  anemia 
characterized  by  depressed  erythropoiesis. 
Particularly, mice that lack the expression of c-kit Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
(the c-kit white spotting mutant, c-kit
w, encodes a 
shortned  protein  lacking  the  transmembrane 
portion, which therefore, fails to  be expressed on 
the cell surface) exhibit a severe reduction of CFU-
E number in the fetal liver and die of anemia around 
day 16 of gestation
28.  Importantly, the transgenic 
expression  of  Epo  can  overcome  the  lethality 
caused by the c-kit
w/w mutation: in the mutant mice 
rescued  by  Epo,  CFU-Es  are rescued  to  normal 
frequencies
29. This  important observation suggests 
that  EpoR  signals  can  partially  bypass  the  strict 
requirement for c-kit signaling in erythropoiesis in 
the absence of c-kit in vivo
29.
SCF  belongs  to  the  family  of  4-helix-bundle 
cytokines  and  growth  factors,  forming  a  non-
covalently associated dimmer, similar in structure to 
M-CSF  and  Flt3L.  SCF  is  synthesized  as  a 
transmembrane-anchored precursor. SCF mRNA is 
alternatively  spliced,  forming  two  different 
transmembrane  precursors,  distinguishable  on  the 
basis  of  their sensitivity to  cell-surface  proteases: 
(a)  the  larger  SCF-M1  contains  a  proteolytic  site 
and generates soluble SCF; (b) the smaller SCF-M2 
lacks  this  proteolytic  site,  giving  rise  to  a 
membrane-bound form. This SCF membrane-bound 
form  is  mainly  involved  in  the  control  of 
hematopoiesis.
The receptor for SCF, c-kit, is a type III receptor 
tyrosine kinase that belongs to the same subfamily 
as PDGFR, Flt3R, M-CSFR. C-kit is expressed in 
the gastrointestinal system, in melanocytes and in 
germ cells. Stimulation of the c-kit receptor with its 
ligand  SCF,  leads  to  receptor  dimerization  and 
activation of its intrinsic tyrosine kinase activity.
C-kit  is  expressed  on  the  majority  of  CD34+ 
hemopoietic  progenitors  and  its  expression  is 
maintained  at  high  levels  during  the stages  of 
differentiation  from  BFU-E  to  CFU-E;  at  later 
stages  of  differentiation  during  the  maturation  of 
CFU-E, c-kit expression progressively declines and 
disappears  in  polychromatophilic  and 
orthochromatic  erythroblasts
30.  These  findings 
imply that SCF may exert effects on erythroid cells 
during  early  and  late  stages  of  erythroid 
differentiation  and  may  act  also  on immature 
erythroid  precursors
30.  Repression  of  c-kit 
expression and signaling at late stages of erythroid 
differentiation  is  mediated  by  the  transcription 
factor GATA-1 through direct interaction with the 
c-kit gene promoter
31.Particularly, it was shown that 
during early stages of erythroid differentiation the 
c-Kit  gene  promoter  is  occupied  by  the  GATA-2 
transcription factors that exerts a stimulatory role on 
the  transcription  of  this  gene;  upon  cell 
differentiation,  GATA-1  displaces  GATA-2  and 
triggers  a  repressive  effect  on  c-kit  gene 
transcription
32.  Other  studies have shown  that  the 
transcription factor PLZF is required, together with 
GATA-2,  for  allowing  elevated  level  of  c-Kit 
expression  during  early  stages  of  erythroid 
differentiation
33 and the microRNA 221 and 222 are 
involved in c-kit downmodulation occurring at late 
stage of erythroid differentiation
34.
SCF/c-kit  interactions  lead  to  c-kit 
autophosphorylation at the level of up to 21 c-kit 
phospho-tyrosine  (PY)  docking  residues  for  SH2 
and PTB domain proteins. Using suitable cell line 
models, studies on c-kit PY mutants have defined 
the specificities of these PY residues: Y719 binds 
p85-PI3K;  Y728  binds  phospholipase  C-;  Y702 
and  Y934  bind  Grb2  and  Grb7  adaptor  binding 
proteins; juxtamembrane Y567 and Y569 sites bind 
SRC family kinases and, through this mechanism, 
activate key survival and proliferation pathways. To 
define  the  biologic  function  of  the  various  PY 
residues  of  c-kit,  mice  carrying  tyrosine-to-
phenylalanine  substitution  mutations  have  been 
generated. These studies have shown that Y569 and 
Y719 residues are not essential for erythropoiesis. 
However, a recent study provided evidence that in 
kit
Y567F/Y567F mice,  steady  state  erythropoiesis  was 
unperturbed,  while  recovery  from  chemically-
induced  anemia  was  markedly  impaired,  thus 
indicating a key role of c-kit in the control of stress 
erythropoiesis
35.
These  observations  clearly  showed  that  c-kit 
signalling  is  important  for  normal  erythropoiesis 
and,  particularly  for  stress  erythropoiesis.  On  the 
other  hand,  numerous  in  vitro and  in  vivo
experiments  have  shown  that  SCF  and  Epo  co-
administration  results  in  a  stimulation  of 
erythropoiesis  and  BFU-E  and  CFU-E  colony 
formation:  particularly,  in  vitro administration  of 
SCF  together  with  Epo  resulted  in  a  marked 
enhancement  of  erythroid  proliferation, associated 
with a delay in erythroid maturation.
Other  studies  have  suggested  that  SCF  could 
potentiate  the  stimulation  of  some  transduction 
pathways  activated  by  Epo. The  studies  aimed  at 
elucidating the synergistic interaction between SCF 
and  Epo  have  proposed  two  main  underlying 
mechanisms. The first mechanism suggests that the 
synergism is mainly related to the sequential role of 
SCF and Epo during erythroid differentiation. The 
second mechanism suggests that SCF and Epo have 
simultaneous, joint effects on the same individual 
cells at  a specific stage of erythroid development 
(proerythroblast  stage).  In  this  context,  recent Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
studies support a model of erythroid differentiation 
in which the effects of SCF and Epo on individual 
erythroid  progenitors/precursors  are  mainly 
sequential and co-signaling (i.e., signaling by both 
cytokines  on  the  same  cells,  resulting  or  not  in 
crosstalk  between  pathways)  has  only  a  limited 
contribution to the final erythroid output
36.
Kit and EpoR mediated co-signaling is essential 
for normal erythroid cell expansion; however, the 
intracellular  signals  that  contribute  to  cooperative 
signaling have been only in part elucidated. Studies 
with mutants of c-kit and EpoR suggest that kit and 
EpoR  mediated  co-signaling  requires  intracellular 
tyrosine residues: particularly, tyrosine residues that 
bind Src kinases in the kit receptor (i.e., Y
567 and 
Y
569 )  appear to  be sufficient for  kit signaling as 
well as co-signaling with EpoR
37.
Activation of PI3K is essential for proliferation 
of erythroid cells. Activated PI3K generates PIP3, 
which serves as an anchor for multiple PH-domain-
containing  proteins,  such  as  protein  kinase  B 
(PKB).  Although  both  SCF  and  Epo  induce 
activation of PI3K in  erythroblasts, the efficiency 
with  which  respective  downstream  signaling 
pathways  are  activated  shows  large  differences: 
particularly,  the activation  of  PKB  is  more
responsive to SCF than to Epo
38,39. PI3K stimulates 
the activation of mTOR and subsequent release of 
the  cap-binding  translation  initiation  factor  4E 
(eIF4E) from the 4E-binding protein 4EBP, which 
controls  the  recruitment  of  structured  mRNA  to 
polysomes.  Enhanced  expression  of  the  eIF4E 
renders  erythroblast  proliferation  independent  of 
PI3K. The activation of eIF4E by SCF determines 
the  selective  association  with  polysomes  of  some 
mRNAs, whose translation is then stimulated. One 
of these mRNAs is represented by Immunoglobulin 
Binding Protein 1 (IGBP1): this gene is involved in 
regulating  erythroid  progenitors  renewal  versus 
differentiation.  In  fact,  the  overexpression  of  this 
gene in erythroid cells mimics the effect of SCF, 
impairing  differentiation  and  promoting  erythroid 
proliferation
40.
SCF  and  Epo  synergistically  activate  MAP 
kinase  (MAP  ERK1/2),  acting  through  different 
molecular  mechanisms
41.  Studies  carried  out  on 
marrow  CFU-E  provided  evidence,  however,  that 
Epo alone resulted in a weak ERK activation, while 
SCF  alone  elicited  a  clear  stimulation  of  ERK 
activity;  the  co-administration  of  both  cytokines 
resulted in  a marked induction of ERK activity
42. 
Interestingly,  the  stimulatory  activity  on  ERK 
activity  exerted  by  the membrane-bound  form  of 
SCF was more pronounced than that elicited by the 
soluble form of SCF
43; in line with this observation, 
the  membrane-associated  SCF  stimulated 
erythropoiesis more efficiently than the soluble SCF 
form. In line with these observations recent studies 
performed on in vitro generated CFU-Es provided 
clear  evidence  that  SCF,  but  not  Epo,  is  able  to 
induce the phosphorylation of MEK
43. This MEK 
activation  does  not  seem  to  be  involved  in  the 
stimulatory  effect  of  SCF  on  erythroid  cell 
proliferation, but is involved in mediating specific 
pathway of gene activation induced by SCF
44.
Furthermore, SCF stimulates  EpoR expression 
and  Stat5  expression,  although  it  was  unable  to 
phosphorylate and then to activate this transcription 
factor
45.  Recent studies  confirmed  that  SCF  was 
unable  to  activate  Stat-5  phosphorylation  and 
products of Stat-5 target genes induced by Epo act 
to  enhance  c-kit  signalling
46.  Stat-5  seems  to  be 
essential for stress erythropoiesis and for mediating 
the  response  to  anemia: EpoR  and  KIT-induced 
Stat5  signals  induce  factors  (such  as  Bcl-x  and 
oncostatin-M) required for the survival of erythroid 
progenitors/precursors
47.
Recent studies suggest that, in addition to Epo 
and  SCF,  also  glucocorticoids  have  a  remarkable 
effect  on  erythropoiesis.  These  hormones  act 
through nuclear receptors and recent investigations 
indicate  that  mice  deficient  in  glucocorticoid 
receptor expression exhibit a complete loss of stress 
erythropoiesis, i.e., the capacity to respond with an 
increased  erythropoietic  production  to  stress 
conditions,  such  as  erythrolysis  or  hypoxia
48.  In 
vitro studies  have  shown  that  glucocorticoids  are 
able  to  exert  a  marked  stimulatory  effect  on 
erythropoiesis: their effect, however, is evident only 
when erythroid cells are grown in the presence of 
both Epo and SCF
49,50. The molecular mechanisms 
responsible  for  the  stimulatory  role  of 
glucocorticoids on erythropoiesis are not precisely 
determined,  but  they  seem  to  involve  an  up 
modulation of  c-kit  and  c-myb  expression
51. 
Interestingly,  p53  antagonizes  the  stimulatory 
activity of glucocorticoids on erythropoiesis
51.
The  mechanism  of  the  cooperative  signaling 
between Epo, KL and glucocorticoids was explored 
by  micro  array  profiling.  This  type  of  analysis 
provided evidence that the majority of the genes are 
modulated by glucocorticoids only in the presence 
of  Epo  and  KL,  suggesting  that  these  hormones 
function  in  the  context  of  large  transactivation 
complexes.  The  basic  effect  of  glucocorticoids 
seems to be mainly related to the induction of genes 
involved in cell renewal and to the attenuation of 
genes  exerting  a  growth-inhibitory  effect
52.  In Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
addition to glucocorticoids also androgens exert a 
stimulatory  effect  on  erythroid  proliferation; 
however, since normal erythroblasts lack androgen 
receptors, the stimulatory effect on these receptors 
on  erythropoiesis  seems  to  be  related  to  the 
usurpation of other nuclear hormone  receptors by 
androgens
53.
The rapid response to anemia does not involve 
only SCF, but also Bone Morphogenetic Protein 4 
(BMP4).  BMP4  is  rapidly,  and  induced 
erythropoiesis  cells  in  the  red  splenic  pulp  of 
anemic  animals  in  response  to  acute  anemia  and 
was found to stimulate immature progenitors to give 
rise  to  Epo-responsive  progenitors.  Studies  in 
animal models have shown that erythroid response 
to acute anemia involves the rapid expansion of a 
specialized  population  of  erythroid  progenitors, 
termed  stress  BFU-E,  mediated  by  BMP4
54.  SCF 
and hypoxia synergize with BMP4 to promote the 
expansion  and  differentiation  of  stress  BFU-E 
during  the  recovery  from  acute  anemia
55.  More 
recently, it was demonstrated that the response of 
erythroid  progenitors  to  BMP4  is  regulated  by 
hedgehog signaling
56.
Effect  of  SCF  Factor  on  Hb  F  synthesis:
Considering  the  pronounced  effects  of  SCF  on 
erythropoiesis  it  seemed  important  to  evaluate  a 
possible effect of this cytokine on HbF synthesis. 
The majority of these studies have been carried out 
by investigating SCF effect in adult erythroid cell 
cultures.
In this regard, the evaluation of cytokine effects 
on erythroblast HbF synthesis requires a stringent 
methodology,  involving  the  use  of  purified 
hemopoietic  progenitors  (usually  human  CD34
+
purified  cells)  and  serum-free  conditions
57-60.  In 
fact, fetal calf serum, routinely used for culture of 
human hemopoietic cells, contains factors able to to
stimulate HbF synthesis
57-60. Furthermore, accessory 
cells present in cultures of unpurified hemopoietic 
progenitors,  may  affect  or  modify  the  effect  of 
exogenous cytokines on HbF synthesis.
In an initial study Miller et al. observed a clear 
stimulation  of  HbF  synthesis  induced  by  SCF  in 
normal (from 0.5% to 6%) and sickle cell anemia 
(from 4 to 6.8%) BFU-Es grown under serum-free 
conditions
61.  These  findings  were  confirmed  and 
extended  by  Peschle  et  al.  using  purified 
hemopoietic  progenitors  grown  under  serum-free 
conditions either in semisolid medium to generate 
BFU-E or in liquid suspension cultures allowing the 
selective  growth  of  erythroid  cells
62.  Using  these 
unilineage culture conditions it was observed that 
SCF  at  optimal  concentrations  (i.e.,  100  ng/ml) 
elicited  a  marked  enhancement  of  HbF  synthesis 
levels up to 20%
62. The stimulatory effect of SCF 
on HbF production could be mediated either by an 
effect on the BFU-E HbF synthesis program or by 
the  recruitment  of  BFU-Es  with  an elevated  HbF 
production  potential.  Experiments  carried  out  on 
single  BFU-Es  provided  evidence  in  favor  of  a 
direct,  dose-related  stimulatory  effect  of  SCF on 
HbF synthesis reactivation
63. In this same study it 
was  shown  that  SCF  was  able  to  synergize  with 
sodium butyrate to enhance HbF synthesis: in fact, 
the  combined addition of the  two agents together 
induced  HbF  synthesis  levels  up  to  40-43%  in 
normal adult erythroid cells
63.
Wojda  et  al.  comparatively  analyzed  twelve 
cytokines  acting  on  erythropoiesis  and  confirmed 
that,  among  them,  only  SCF  was  able  to 
significantly enhance HbF synthesis
64. The capacity 
of  SCF  to  reactivate    HbF  synthesis  in  adult 
erythroblasts was correlated to the presence of c-kit 
on  erythroid  progenitors/precursors:  in  fact,  the 
delayed addition of SCF to erythroid cultures was 
active in inducing a marked enhancement of HbF 
synthesis only if added on erythroid cell progeny c-
kit
+64.  Subsequent  studies  have  shown  the 
synergistic effect between SCF and other agents in 
stimulating  HbF  synthesis.  Two  molecules, 
Transforming  Growth  Factor- (TGF-)  and 
corticosteroids, potentiate the effect of SCF on HbF 
synthesis.  Thus, despite  their  opposite  effects  on 
erythroid  cell  growth,  SCF  and  TGF- had 
synergistic effects with respect to HbF synthesis
65. 
In  erythroid  cultures  supplemented  with 
Epo+SCF+TGF- about  a  40%  of  HbF  synthesis 
was  observed,  with  a  pancellular  distribution  of 
HbF  in  erythroid  cells
65.  The  evaluation  of 
glucocorticoids effects on HbF synthesis, alone or 
in  cooperation  with  SCF,  was  prompted  from 
studies  showing  that  corticosteroids,  such  as 
dexamethasone,  cooperate  with  Epo  and  SCF  to 
enhance  and  sustain  the  proliferation of  erythroid 
progenitors
66. Dexamethasone when added together 
with Epo and SCF enhanced HbF synthesis up to 
55%; furthermore, analysis of erythroid cultures of 
sibling BFU-Es showed that the stimulatory effect 
of  Dexamethasone+SCF  was  related  to  the 
modulation  of  -globin  expression  rather  than  to 
recruitment of BFU-Es with elevated HbF synthetic 
potential
67.
The effect of SCF was recently investigated in 
cultures  of  -thalassemic  erythroid  cells.  In 
erythroid  cultures  of  -thalassemic  patients, 
addition  of  SCF  (in  the  presence  of  Epo), Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
remarkably  stimulated  cell  proliferation  (3-4  logs 
over control cultures), decreased the percentage of 
apoptotic and dyserythropoietic cells and markedly 
increased -globin synthesis, reaching levels 3-fold 
higher  than  in  control  cultures  (from  27%  to 
81%)
65. These studies indicate that in -thalassemia 
SCF  induces  an  expansion  of  effective 
erythropoiesis and the reactivation of HbF synthesis 
up to fetal levels and may hence  considered as a 
therapeutic agent for this disease
68.
The mechanisms through which SCF stimulates 
HbF  synthesis  in  adult  erythroid  cells  is  largely 
unknown. It is evident that the mechanism of HbF 
induction by SCF must be related to one or several 
signaling  pathways  induced  by  the  interaction  of 
this cytokine with its receptor c-kit. In this context, 
Bhanu et al
69 evaluated the effect of inhibitors of 
various signaling pathways, including JAK2, PKC, 
PI3K,  p38MAPK,  guanylate  cyclase  and  MEK 
inhibitors.  Only  MEK  inhibitors  elicited  a 
pronounced inhibitory effect on HbF synthesis, thus 
indicating  that  phosphorylation  of  ERK-1/ERK-2 
MAPK plays an essential role in the mechanisms 
through  which  SCF  activates  -globin  gene 
expression in adult erythroid cells. At variance with 
SCF, the large majority of the other HbF chemical 
inducers  activate p38  MAPK cell  stress  signaling 
pathway  and  this  pathway  is  required  for  their 
stimulatory effect on HbF synthesis
70.
Among the large number of proteins binding to 
the  -globin  promoter  region,  it  was  recently 
demonstrated  that  stage-specifically  expressed 
nuclear  receptor  chicken  ovalbumin  upstream 
promoter- transcription factor II (COUP-TFII) and 
the direct repeat erythroid definitive binding protein 
TR2/TR4,  are  implicated  in SCF-mediated  HbF 
reactivation
67.  Particularly,  it  was  shown  that 
COUP-TFII  expression  is  suppressed  by  SCF 
through  phosphorylation  of  serine/threonine 
phosphatase  and  this  event  is  required  for  SCF-
induced  HbF  reactivation
71.  This  finding  may  be 
linked to the previous studies on the role of ERK1/2 
on  SCF-mediated  HbF  induction.  In  fact,  SCF, 
through  stimulation  of  ERK1/2  MAPK  signaling 
pathway,  regulates  the  downstream  repressor 
COUP-TFII  by  inhibiting  serine/threonine 
phosphatase 2A activity and the decreased COUP-
TFII expression resulted in -globin reactivation
71.
Other studies have suggested a possible role of 
some  transcription  factors  whose  expression  is 
induced by SCF, such as Id2, Tal-1 and FKLF in 
mediating  the  transcriptional  activation  of  the 
human -globin gene 
63,67. A recent study provided 
evidence  that  SCF  treatment  of  adult  erythroid 
progenitors was associated with consistent changes 
of  globin  gene  histones  and  with  a  concomitant 
transcriptional  activation  pathway  involving 
reproducible changes in expression of some nuclear 
transcription factors that are recognized regulators 
of  erythropoiesis  or  globin  genes  (MAFF,  Id2, 
HHEX,  SOX6  and  EGR1)
72.  Interestingly,  in  this 
thudy an inhibitory effect of SCF on the expression 
of BCL11A mRNA expression was reported
72.
These SCF in  vitro observations  must  be 
extended  to  in  vivo studies  in  order  to  evaluate 
optimal  doses, schedules of administration and side 
effects. In this context, combined doses of SCF and 
Epo have been administered to baboons, achieving 
up  to  20%  HbF  levels
73.  Preclinical  studies  in 
primates and mice suggested that SCF occasionally 
causes  significant  allergic  side  effects,  related  to 
induction of mastocytosis
74,75. This was confirmed 
by  subsequent  clinical  trials  in  HIV  and  cancer 
patients
76,77,  aplastic  anemia
78,  cord  blood 
transplantation
79 and  postablative  chemotherapy
80: 
specifically, mild allergic reactions  (e.g., pruritus, 
urticaria, cutaneous angioedema) were reported in a 
minority  of  patients,  while  severe  ones  (e.g., 
laringospasm)  were  observed  only  in  exceptional 
cases. In the most extensive phase 3 trial, SCF was 
used  for  stem cell  mobilization:  patients  received 
recombinant  SCF  at  20  g/kg  per  day  for  5 
consecutive days and 3 of them reported systemic 
allergic  reactions,  resolved after  treatment  with 
steroids
81. The potential use of SCF for treatment of 
-thalassemic or sickle cell anemia patients implies 
a  chronic  administration  protocol,  based  on 
sequential intermittent therapy cycles: this protocol 
may amplify the potential risk of allergic reactions 
and must be considered cautiously in view of these 
possible side effects.
It is of interest to note that recent studies have 
involved the SCF/c-kit system in the mechanism of 
physiologic hemoglobin switching.    First, it was 
observed that the level of c-kit and SCF expression 
is particularly elevated during embryonic/fetal life 
at  the  level  of  tissues  involved  in  hematopoiesis 
(AGM  region  and  fetal  liver)
82.  Second,  it  was 
reported  that  cord  blood  serum  contains  clearly 
higher SCF levels than adult serum, a phenomenon 
seemingly  related  to  the  capacity  of  human 
umbilical  vein  endothelial  cells  to  release  large 
amounts of SCF
83-85. Third, c-kit expression on cord 
blood CD34
+ cells gradually declines: this decrease 
is  directly  related  to  the  decline  of  HbF  content. 
This decline of c-kit expression is paralleled by a 
concomitant  gradual  decrease  of  SCF  levels 
(Gabbianelli  M  et  al,  unpublished  observations). Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Altogether these observations suggest that a decline 
of kit activity could play a role in the mechanism of 
perinatal HbFHbA hemoglobin switching. In line 
with this hypothesis, addition of SCF in cord blood 
BFU-E  cultures  reactivates  HbF  production  in  a 
dose-dependent fashion, almost up to the pre-switch 
levels  (Gabbianelli  M  et  al,  unpublished 
observations).The  mechanisms  underlying  the 
modulation of c-kit expression during ontogenesis 
could  be,  at  least  in  part,  related  to  the  c-kit 
suppressing  miR221/miR222  complex  ,  whose 
levels increased during development (Gabbianelli et 
al, unpublished observations). Interestingly, a recent 
study by Bianchi et al
86 suggested that the hypoxia-
associated miR210 might be involved in increased 
expression  of  γ-globin  genes  in  differentiating 
erythroid  cells.  At  the  moment  it  is  unknown 
whether  miR210 expression  is  controlled by SCF 
and  is  modulated  in  erythroid  cells  during 
ontogenesis,  and  particularly  during  the  Hb 
switching period.
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